Debra L. Richardson

University of Oklahoma Health Sciences Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study”.

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study

Gynecologic Oncology(2021)10.1016/j.ygyno.2021.01.025

N/A

2.5DataRank · unranked

85 citations

Virginia L. Filiaci, Adrianne Mallen, Kristina W. Thiel, Eric J. Devor, Katherine Moxley +17 more

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.04.578

N/A

0.399DataRank · unranked

12 citations

Debra L. Richardson, Andrea R. Hagemann, Robert W. Holloway, Mark S. Reed, Melanie K Bergman +21 more

Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5502

N/A

0DataRank · unranked

13 citations

Wei Deng, Loren K. Mell, Debra L. Richardson, Joan L. Walker, Laura L. Holman +15 more

Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5525

N/A

0DataRank · unranked

1 citations

Andrew B. Nixon, Danielle Enserro, David Bender, B.J. Rimel, Matthew A. Powell +12 more

A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5629

N/A

0DataRank · unranked

1 citations

David Bender, Danielle Enserro, Shannon N. Westin, Debra L. Richardson, Laura L. Holman +10 more

Harnessing ovarian cancer ascites for translational science: models, biomarkers, and therapeutics

Molecular Cancer(2025)10.1186/s12943-025-02438-z

N/A

0DataRank · unranked

7 citations

Laura Adhikari, Doris M. Benbrook, Jacqueline A. Bohn, Anthony W. G. Burgett, Vishal Chandra +9 more

105P Immune biomarker analysis of the OVATION-2 trial, a randomized phase I/II study of IL-12 gene therapy IMNN-001 in combination with neo/adjuvant chemotherapy (NACT) in newly-diagnosed advanced epithelial ovarian cancer (EOC)

ESMO Open(2025)10.1016/j.esmoop.2025.105233

N/A

0DataRank · unranked

1 citations

Debra L. Richardson, Andrea R. Hagemann, Robert W. Holloway, Bhavana Pothuri, Jennifer Scalici +14 more

Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?

Gynecologic Oncology(2020)10.1016/j.ygyno.2019.12.028

N/A

0DataRank · unranked

19 citations

Ting‐Tai Yen, Rebecca L. Stone, Stephanie L. Wethington, Caitlin Carr, Ji Son +24 more

Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.10.021

N/A

0DataRank · unranked

0 citations

Shailendra Kumar Dhar Dwivedi, Camille Gunderson-Jackson, Joan L. Walker, Robert S. Mannel, L.L. Holman +11 more

A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.04.016

N/A

0DataRank · unranked

19 citations

Kathleen N. Moore, Leigh A. Cantrell, Britt Erickson, Linda Duska, Debra L. Richardson +10 more